SAGE News and Press, Sage Therapeutics Inc. From 08/01/22

Sage Therapeutics ( NASDAQ: SAGE ) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, before market open. EPS Estimate is -$2.15 (-17.5% Y/Y) and the consensus Revenue Estimate is $1.77M (+7.9% Y/Y). has beaten EPS estimates 50% of the time and has beaten...

July Update: FTSE Russell Index Reconstitution Anomaly - Strong First Month Results. The trading test of the Chinco & Sammon (2022) anomaly study so far is delivering much better results than the published journal research. Over 85% of the expected abnormal return portfolio is...

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, August 2, 2022 at 8:00 a.m. ET to announce second quarter 2022 financial results and discuss recen...

Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the development of novel therapies to treat central nervous sys...

Commercial-stage biotech Sage Therapeutics (NASDAQ:SAGE) announced on Monday that the company will submit a single new drug application (NDA) to the FDA for zuranolone, a candidate the company developed with Biogen (BIIB) for two forms of depression. In April, the partners began the rolling s...

Shares of Sage Therapeutics (NASDAQ: SAGE) , a biopharmaceutical company that specializes in brain disorder therapies, saw its shares rise 15.6% this week, according to data from S&P Global Market Intelligence . The stock closed last Friday at $32.24 but rose to $37.27 this ...

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the following upcoming investor conferences in June: Jefferies Healthcare Conference (New York, NY): fir...

Zuranolone 50 mg demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints Zuranolone 50 mg was generally well-tolerated and demonstrated a safety pr...

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will give a presentation at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 8:00am PT...

Sage Therapeutics, Inc. (SAGE) Q1 2022 Earnings Conference Call May 03, 2022 08:00 AM ET Company Participants Helen Rubinstein - Investor Relations Barry Greene - Chief Executive Officer Jim Doherty - Chief Development Officer Kimi Iguchi - Chief Financial Officer Chris Benecchi - Chief Comme...